Version history

{
  "session_id": "sess_SDA-2026-04-02-gap-2026-04-01-gap-006_task_9aae8fc5",
  "round_number": 4,
  "agent_persona": "persona-synthesizer",
  "agent_backend": "scidex.core.llm.complete",
  "action": "synthesize",
  "content": "{\n  \"ranked_hypotheses\": [\n    {\n      \"title\": \"cGAS-STING Pathway Hyperactivation Mediates Tau Propagation\",\n      \"description\": \"Pathological tau triggers cytosolic DNA release and mitochondrial DNA stress, activating cGAS-STING signaling in neurons and microglia. This creates a feedforward inflammatory loop that accelerates tau pathology spread and impairs neuronal proteostasis. Tier 1 translational feasibility with 5-8 year development timeline.\",\n      \"target_gene\": \"cGAS (CGAS), STING (TMEM173)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.76,\n        \"novelty\": 0.70,\n        \"feasibility\": 0.82,\n        \"therapeutic_potential\": 0.75,\n        \"mechanistic_plausibility\": 0.72,\n        \"druggability\": 0.78,\n        \"safety_profile\": 0.65,\n        \"competitive_landscape\": 0.80,\n        \"data_availability\": 0.75,\n        \"reproducibility\": 0.78\n      },\n      \"composite_score\": 0.76,\n      \"evidence_for\": [\n        {\"claim\": \"cGAS-STING activation detected in P301S tauopathy mice\", \"pmid\": \"32142648\"},\n        {\"claim\": \"Cytosolic mtDNA accumulation observed in neurodegeneration\", \"pmid\": \"29643778\"},\n        {\"claim\": \"STING inhibition reduces neuroinflammation and improves behavior in models\", \"pmid\": \"32817599\"},\n        {\"claim\": \"Type I interferon response genes upregulated in AD and Pick's disease brains\", \"pmid\": \"33277574\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"STING inhibitors may impair peripheral antiviral immunity with chronic CNS dosing\", \"pmid\": \"N/A\"},\n        {\"claim\": \"Mouse CNS immune architecture differs from human; microglial density not fully conserved\", \"pmid\": \"N/A\"}\n      ]\n    },\n    {\n      \"title\": \"TREM2-Dependent Microglial State Transition as Therapeutic Window in Alzheimer's Disease\",\n      \"description\": \"Heterozygous TREM2 loss-of-function variants impair transition of microglia from homeostatic to disease-associated (DAM) state, preventing effective phagocytosis of amyloid plaques. Enhancing TREM2 signaling may restore neuroprotective microglial functions. Tier 2 feasibility with moderate-high druggability via agonist antibodies.\",\n      \"target_gene\": \"TREM2, SYK signaling pathway\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.78,\n        \"novelty\": 0.65,\n        \"feasibility\": 0.68,\n        \"therapeutic_potential\": 0.72,\n        \"mechanistic_plausibility\": 0.61,\n        \"druggability\": 0.70,\n        \"safety_profile\": 0.60,\n        \"competitive_landscape\": 0.75,\n        \"data_availability\": 0.72,\n        \"reproducibility\": 0.68\n      },\n      \"composite_score\": 0.69,\n      \"evidence_for\": [\n        {\"claim\": \"TREM2 R47H variant increases AD risk ~3-fold\", \"pmid\": \"23350616\"},\n        {\"claim\": \"Single-cell RNA-seq reveals impaired DAM formation in Trem2-deficient mice\", \"pmid\": \"28120864\"},\n        {\"claim\": \"Trem2 knockout mice show increased amyloid seeding\", \"pmid\": \"29431764\"},\n        {\"claim\": \"TREM2-agonist antibodies promote microglial amyloid uptake\", \"pmid\": \"33850021\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Human Nasu-Hakola disease (complete TREM2 deficiency) doesn't show classical amyloid-driven AD\", \"pmid\": \"N/A\"},\n        {\"claim\": \"DAM as cause vs consequence remains unresolved\", \"pmid\": \"N/A\"},\n        {\"claim\": \"Mixed human imaging data on amyloid burden in TREM2 variant carriers\", \"pmid\": \"32019990\"},\n        {\"claim\": \"TREM2 deficiency can be protective in EAE contexts\", \"pmid\": \"26385461\"}\n      ]\n    },\n    {\n      \"title\": \"Astrocyte-Neuron Metabolic Coupling Failure Precedes Neurodegeneration in FTD-GRN\",\n      \"description\": \"Progranulin haploinsufficiency in FTD impairs astrocyte lactate production via MCT4, reducing neuronal glucose uptake and making neurons vulnerable to metabolic stress. Tier 2 feasibility with reasonable therapeutic entry points.\",\n      \"target_gene\": \"GRN, SLC16A3 (MCT4)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.71,\n        \"novelty\": 0.72,\n        \"feasibility\": 0.66,\n        \"therapeutic_potential\": 0.68,\n        \"mechanistic_plausibility\": 0.70,\n        \"druggability\": 0.62,\n        \"safety_profile\": 0.68,\n        \"competitive_landscape\": 0.70,\n        \"data_availability\": 0.65,\n        \"reproducibility\": 0.72\n      },\n      \"composite_score\": 0.69,\n      \"evidence_for\": [\n        {\"claim\": \"Grn-/- mice show astrocyte dysfunction and lysosomal abnormalities\", \"pmid\": \"21994255\"},\n        {\"claim\": \"Progranulin localizes to astrocytes, particularly around synapses\", \"pmid\": \"20819946\"},\n        {\"claim\": \"Astrocyte-neuron lactate shuttle critical for synaptic activity\", \"pmid\": \"24969124\"},\n        {\"claim\": \"MCT4 expression reduced in Grn knockout mice\", \"pmid\": \"33727733\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Metabolic coupling mechanisms may not be primary drivers, requiring validation of causal sequence\", \"pmid\": \"N/A\"},\n        {\"claim\": \"MCT4 targeting may affect peripheral lactate metabolism\", \"pmid\": \"N/A\"}\n      ]\n    },\n    {\n      \"title\": \"Nuclear TDP-43 Depletion Drives Synaptic Splicing Dysregulation in ALS-FTD\",\n      \"description\": \"TDP-43 proteinopathy leads to progressive nuclear depletion, causing widespread alternative splicing defects at synapses. Despite highest original confidence (0.82), mechanistic critiques reveal causality gaps. ASO-based approach is Tier 3 with 10-12 year timeline.\",\n      \"target_gene\": \"TARDBP, splicing targets (Sortilin1, Synaptojanin1)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.82,\n        \"novelty\": 0.55,\n        \"feasibility\": 0.52,\n        \"therapeutic_potential\": 0.58,\n        \"mechanistic_plausibility\": 0.58,\n        \"druggability\": 0.68,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.65,\n        \"data_availability\": 0.75,\n        \"reproducibility\": 0.62\n      },\n      \"composite_score\": 0.62,\n      \"evidence_for\": [\n        {\"claim\": \"TDP-43 aggregates found in ~95% of ALS and ~50% of FTD cases\", \"pmid\": \"19270868\"},\n        {\"claim\": \"Nuclear TDP-43 loss precedes cytoplasmic aggregation in patient-derived neurons\", \"pmid\": \"28712719\"},\n        {\"claim\": \"Conditional TDP-43 knockdown in mice reproduces ALS phenotypes\", \"pmid\": \"22958898\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Gain-of-function TARDBP mutations suggest toxic gain rather than pure loss-of-function\", \"pmid\": \"24854211\"},\n        {\"claim\": \"Forcing nuclear retention of mutant TDP-43 didn't prevent degeneration\", \"pmid\": \"26656189\"},\n        {\"claim\": \"Specificity problem: splicing dysregulation should be ubiquitous if TDP-43 regulates thousands of splicing events globally\", \"pmid\": \"N/A\"},\n        {\"claim\": \"ASO strategies targeting RNA metabolism have failed or stalled in ALS trials\", \"pmid\": \"N/A\"}\n      ]\n    },\n    {\n      \"title\": \"Autophagosome-Lysosome Fusion Defects as Primary Driver of α-Synuclein Propagation\",\n      \"description\": \"VPS41 and HOPS complex dysfunction impairs autophagosome-lysosome fusion, causing accumulation of α-synuclein oligomers and increased exosome release. Mechanistically plausible but causality direction remains ambiguous. Tier 3 feasibility.\",\n      \"target_gene\": \"VPS41, STX17, HOPS complex, TRPML1 (MCOLN1)\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.75,\n        \"novelty\": 0.68,\n        \"feasibility\": 0.58,\n        \"therapeutic_potential\": 0.65,\n        \"mechanistic_plausibility\": 0.58,\n        \"druggability\": 0.60,\n        \"safety_profile\": 0.62,\n        \"competitive_landscape\": 0.68,\n        \"data_availability\": 0.60,\n        \"reproducibility\": 0.62\n      },\n      \"composite_score\": 0.63,\n      \"evidence_for\": [\n        {\"claim\": \"VPS41 variants associated with Parkinson's disease risk\", \"pmid\": \"28739685\"},\n        {\"claim\": \"Lysosomal GBA variants cause 20-fold increased PD risk\", \"pmid\": \"30664766\"},\n        {\"claim\": \"TRPML1 agonists (ML-SA1) enhance lysosomal function and reduce α-synuclein in mouse models\", \"pmid\": \"31109921\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"Bidirectional causality: α-synuclein accumulation may itself impair lysosomal function\", \"pmid\": \"N/A\"},\n        {\"claim\": \"VPS41 GWAS evidence has modest effect sizes with unclear functional validation\", \"pmid\": \"N/A\"},\n        {\"claim\": \"Mechanistic link between impaired fusion and increased exosome release is asserted but not demonstrated\", \"pmid\": \"N/A\"}\n      ]\n    },\n    {\n      \"title\": \"circHomer1a Restoration as Neuroprotective Strategy in Synaptic Decline\",\n      \"description\": \"circHomer1a reduction in AD/FTD impairs miR-1961 sponging, reducing HOMER1 translation essential for NMDA receptor signaling. Despite intriguing correlative data, mechanistic chain requires validation at each step. Tier 5 feasibility with 15+ year timeline.\",\n      \"target_gene\": \"circHomer1a, miR-1961, HOMER1\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.68,\n        \"novelty\": 0.80,\n        \"feasibility\": 0.40,\n        \"therapeutic_potential\": 0.55,\n        \"mechanistic_plausibility\": 0.44,\n        \"druggability\": 0.38,\n        \"safety_profile\": 0.55,\n        \"competitive_landscape\": 0.72,\n        \"data_availability\": 0.52,\n        \"reproducibility\": 0.45\n      },\n      \"composite_score\": 0.54,\n      \"evidence_for\": [\n        {\"claim\": \"circHomer1a significantly decreased in AD prefrontal cortex\", \"pmid\": \"30012402\"},\n        {\"claim\": \"circHomer1a overexpression improves synaptic plasticity in hippocampal neurons\", \"pmid\": \"29670289\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"circRNA function may be artifact of overexpression systems; many reported functions failed replication\", \"pmid\": \"N/A\"},\n        {\"claim\": \"HOMER1 itself unchanged—if circHomer1a→HOMER1 mechanism true, protein should also be reduced\", \"pmid\": \"N/A\"},\n        {\"claim\": \"AAV9 targeting to cortical neurons in adult mice is inefficient\", \"pmid\": \"N/A\"},\n        {\"claim\": \"miR-1961 sponging affinity and capacity not biophysically quantified\", \"pmid\": \"N/A\"}\n      ]\n    },\n    {\n      \"title\": \"N-acetylation Deficiency as Novel Metabolic Vulnerabilities in Sporadic ALS\",\n      \"description\": \"Post-translational N-terminal acetylation defects contribute to motor neuron degeneration in sporadic ALS. However, no direct genetic link to ALS exists, and mechanistic gap from Ogden syndrome (childhood lethal) to late-onset sporadic ALS is unexplained. Tier 4 exploratory.\",\n      \"target_gene\": \"NAA10, NAA20, NAA80\",\n      \"dimension_scores\": {\n        \"evidence_strength\": 0.62,\n        \"novelty\": 0.85,\n        \"feasibility\": 0.42,\n        \"therapeutic_potential\": 0.50,\n        \"mechanistic_plausibility\": 0.48,\n        \"druggability\": 0.35,\n        \"safety_profile\": 0.45,\n        \"competitive_landscape\": 0.78,\n        \"data_availability\": 0.48,\n        \"reproducibility\": 0.52\n      },\n      \"composite_score\": 0.54,\n      \"evidence_for\": [\n        {\"claim\": \"NAA10 mutations cause Ogden syndrome with neurodegenerative features\", \"pmid\": \"22581936\"},\n        {\"claim\": \"N-terminal acetylation deficiency linked to proteostasis failure in neurodegeneration\", \"pmid\": \"29395064\"},\n        {\"claim\": \"Mitochondrial-localized NATs regulate mitophagy\", \"pmid\": \"30629168\"},\n        {\"claim\": \"Global acetylome changes observed in ALS spinal cord\", \"pmid\": \"28855058\"}\n      ],\n      \"evidence_against\": [\n        {\"claim\": \"No direct genetic enrichment of NAA10/NAA20 in ALS patient cohorts\", \"pmid\": \"N/A\"},\n        {\"claim\": \"Mechanistic gap from catastrophic developmental syndrome to late-onset adult neurodegeneration unexplained\", \"pmid\": \"N/A\"},\n        {\"claim\": \"N-acetylation is pervasive; doesn't explain motor neuron specificity\", \"pmid\": \"N/A\"}\n      ]\n    }\n  ],\n  \"knowledge_edges\": [\n    {\"source_id\": \"SDA-2026-04-02-gap-2026-04-01-gap-006\", \"source_type\": \"analysis\", \"target_id\": \"hypothesis_1\", \"target_type\": \"hypothesis\", \"relation\": \"generates\"},\n    {\"source_id\": \"SDA-2026-04-02-gap-2026-04-01-gap-006\", \"source_type\": \"analysis\", \"target_id\": \"hypothesis_2\", \"target_type\": \"hypothesis\", \"relation\": \"generates\"},\n    {\"source_id\": \"SDA-2026-04-02-gap-2026-04-01-gap-006\", \"source_type\": \"analysis\", \"target_id\": \"hypothesis_3\", \"target_type\": \"hypothesis\", \"relation\": \"generates\"},\n    {\"source_id\": \"SDA-2026-04-02-gap-2026-04-01-gap-006\", \"source_type\": \"analysis\", \"target_id\": \"hypothesis_7\", \"target_type\": \"hypothesis\", \"relation\": \"generates\"},\n    {\"source_id\": \"hypothesis_7\", \"source_type\": \"hypothesis\", \"target_id\": \"cGAS\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_7\", \"source_type\": \"hypothesis\", \"target_id\": \"STING\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_2\", \"source_type\": \"hypothesis\", \"target_id\": \"TREM2\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_1\", \"source_type\": \"hypothesis\", \"target_id\": \"TARDBP\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_3\", \"source_type\": \"hypothesis\", \"target_id\": \"VPS41\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_3\", \"source_type\": \"hypothesis\", \"target_id\": \"MCOLN1\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_6\", \"source_type\": \"hypothesis\", \"target_id\": \"GRN\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_6\", \"source_type\": \"hypothesis\", \"target_id\": \"SLC16A3\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_5\", \"source_type\": \"hypothesis\", \"target_id\": \"NAA10\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_4\", \"source_type\": \"hypothesis\", \"target_id\": \"HOMER1\", \"target_type\": \"gene\", \"relation\": \"targets\"},\n    {\"source_id\": \"hypothesis_1\", \"source_type\": \"hypothesis\", \"target_id\": \"hypothesis_2\", \"target_type\": \"hypothesis\", \"relation\": \"shares_neuroimmune_mechanisms_with\"},\n    {\"source_id\": \"hypothesis_3\", \"source_type\": \"hypothesis\", \"target_id\": \"hypothesis_6\", \"target_type\": \"hypothesis\", \"relation\": \"shares_lysosomal_pathway_with\"},\n    {\"source_id\": \"hypothesis_5\", \"source_type\": \"hypothesis\", \"target_id\": \"hypothesis_3\", \"target_type\": \"hypothesis\", \"relation\": \"shares_proteostasis_with\"},\n    {\"source_id\": \"TREM2\", \"source_type\": \"gene\", \"target_id\": \"hypothesis_2\", \"target_type\": \"hypothesis\", \"relation\": \"implicated_in\"},\n    {\"source_id\": \"cGAS\", \"source_type\": \"gene\", \"target_id\": \"hypothesis_7\", \"target_type\": \"hypothesis\", \"relation\": \"implicated_in\"},\n    {\"source_id\": \"TARDBP\", \"source_type\": \"gene\", \"target_id\": \"hypothesis_1\", \"target_type\": \"hypothesis\", \"relation\": \"implicated_in\"}\n  ],\n  \"synthesis_summary\": \"The Agora debate reveals a critical divergence between mechanistic confidence (dominated by TDP-43 nuclear loss at 0.82) and translational feasibility (favoring cGAS-STING at Tier 1). The Skeptic's critiques substantially revise mechanistic confidence downward for Hypotheses 1-4, identifying foundational issues including causality assumption (TDP-43), bidirectional causation (lysosome-αSyn), and epiphenomenon risk (circHomer1a). For drug development prioritization, cGAS-STING emerges as the most translationally mature pathway with Tier 1 feasibility, active STING inhibitor programs, quantifiable CSF biomarkers (IP-10, IFN-β), and a 5-8 year Phase II timeline. TREM2 microglial state transition (Hypothesis 2) and astrocyte-neuron metabolic coupling (Hypothesis 6) represent Tier 2 opportunities with moderate-high druggability but unresolved mechanistic questions regarding DAM causality and therapeutic windows. TDP-43 splicing despite highest original confidence warrants caution given sufficiency gaps and ASO trial failures; if pursued, conditional splice correction experiments in adult mice after symptom onset represent the critical falsifying experiment before committing to antisense strategies.\"\n}",
  "tokens_used": "3983",
  "persona_id": "persona-synthesizer"
}